| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
The primary molecular target of Deprodone propionate is the glucocorticoid receptor. As a corticosteroid, Deprodone propionate binds to the glucocorticoid receptor, which is a nuclear receptor that regulates gene transcription. Upon binding, the receptor-ligand complex translocates to the nucleus and modulates the expression of genes involved in inflammation and immune responses. This leads to the suppression of pro-inflammatory cytokines and the inhibition of immune cell activation. The compound's non-halogenated structure is suggested to reduce the incidence and severity of local side effects compared to halogenated corticosteroids.
|
|---|---|
| ln Vitro |
As a potent ingredient, deprodone propionate can work for extended periods of time, exhibit maximum effect, cause no skin irritation, and have physicochemical stability. Because of the suspending agent's thickening effect, deprodone propionate can be kept in a state of stable suspension[1].
In vitro studies demonstrate that Deprodone propionate exhibits significant anti-inflammatory activity. As a corticosteroid, it suppresses the production of pro-inflammatory cytokines and inhibits the activation of immune cells. The compound's potency and efficacy have been demonstrated in various in vitro models of inflammation. Its non-halogenated structure is suggested to reduce the incidence and severity of local side effects. The compound is used as an active pharmaceutical ingredient in topical formulations for the treatment of inflammatory and allergic skin conditions. Its physicochemical stability and lack of skin irritation make it a suitable choice for dermatological applications. |
| ln Vivo |
In vivo studies of Deprodone propionate have demonstrated its efficacy in animal models of inflammation. As a topical corticosteroid, it is used in the treatment of various inflammatory and allergic conditions. The compound can work for extended periods of time and exhibit maximum effect with no skin irritation. In vivo protocols typically involve topical application of Deprodone propionate in a suitable formulation (e.g., cream or ointment) to the affected area. Endpoints include assessment of inflammation, skin irritation, and histopathological examination. The compound's safety and efficacy have been established in preclinical and clinical studies.
|
| Enzyme Assay |
For anti-inflammatory assays, immune cells (e.g., macrophages, lymphocytes) are cultured in appropriate medium and stimulated with LPS or other inflammatory stimuli in the presence or absence of Deprodone propionate (0.001-10 µM). After 4-24 hours, culture supernatants are collected, and cytokine levels (TNF-α, IL-1β, IL-6) are measured by ELISA. For receptor binding assays, the affinity of Deprodone propionate for the glucocorticoid receptor can be measured using radioligand binding assays. Cells expressing the glucocorticoid receptor are incubated with [³H]-dexamethasone and varying concentrations of Deprodone propionate. Bound and free radioligand are separated, and radioactivity is counted. IC50 values are calculated from dose-response curves.
|
| Cell Assay |
For cellular studies, immune cells or skin cells (e.g., keratinocytes, fibroblasts) are cultured in appropriate medium (DMEM or RPMI-1640) with 10% FBS and antibiotics. Cells are seeded in 6-well or 96-well plates. Deprodone propionate is dissolved in DMSO and diluted in culture medium to final concentrations (typically 0.001-10 µM). Cells are pre-treated with the compound for 1-2 hours, then stimulated with LPS (0.1-1 µg/ml) or other inflammatory stimuli for 4-24 hours. Cytokine production is measured by ELISA. Cell viability is assessed by MTT assay. For mechanistic studies, cells are lysed and analyzed for glucocorticoid receptor activation and downstream signaling proteins by Western blot.
|
| Animal Protocol |
For in vivo efficacy studies, animal models of inflammation (e.g., carrageenan-induced paw edema, contact hypersensitivity) are used. Deprodone propionate is formulated in a suitable vehicle (e.g., cream, ointment, or solution) and applied topically to the affected area. Doses and treatment schedules are determined from preliminary studies. Inflammation is assessed by measuring paw swelling, skin thickness, or other appropriate endpoints. Histopathological examination of skin tissues is performed to assess inflammatory cell infiltration and tissue damage. For pharmacokinetic studies, blood and tissue samples are collected at various time points for compound quantification by LC-MS.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for Deprodone propionate indicate that it is a topical corticosteroid with limited systemic absorption. When applied topically, the compound is absorbed through the skin and metabolized in the liver. Its systemic bioavailability is low, reducing the risk of systemic side effects. The compound's pharmacokinetic properties support its use as a topical anti-inflammatory agent. The compound can work for extended periods of time due to its physicochemical stability.
|
| Toxicity/Toxicokinetics |
Toxicological data for Deprodone propionate are derived from preclinical and clinical studies. As a corticosteroid, the compound can cause local side effects such as skin atrophy, telangiectasia, and striae with prolonged use. Systemic side effects are rare due to low systemic absorption. The compound's non-halogenated structure is suggested to reduce the incidence and severity of local side effects. It causes no skin irritation. The compound is contraindicated in patients with skin infections or hypersensitivity to corticosteroids.
|
| Additional Infomation |
Dipron propionate is a corticosteroid hormone.
Deprodone propionate (CAS 20424-00-4), also known as RD20000, is a synthetic non-halogenated topical corticosteroid. It has a molecular formula of C₂₄H₃₂O₅ and a molecular weight of 400.51. The compound is a potent anti-inflammatory agent that suppresses the immune response to inflammation. It is used in the treatment of various inflammatory and allergic skin conditions. Its non-halogenated structure reduces the incidence and severity of local side effects. Deprodone propionate can work for extended periods with no skin irritation. It is strictly for research use only. |
| Molecular Formula |
C24H32O5
|
|---|---|
| Molecular Weight |
400.51
|
| Exact Mass |
400.225
|
| CAS # |
20424-00-4
|
| PubChem CID |
443972
|
| Appearance |
White to off-white solid powder
|
| Density |
1.2 g/cm3
|
| Boiling Point |
540.6ºC at 760 mmHg
|
| Flash Point |
180.9ºC
|
| Vapour Pressure |
6.07E-14mmHg at 25°C
|
| Index of Refraction |
1.566
|
| LogP |
3.546
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
29
|
| Complexity |
825
|
| Defined Atom Stereocenter Count |
7
|
| SMILES |
C[C@@]12[C@@](C(C)=O)(CC[C@@]1([H])[C@@]3([H])[C@]([C@@]4(C(CC3)=CC(C=C4)=O)C)([H])[C@@H](O)C2)OC(CC)=O
|
| InChi Key |
DRSFVGQMPYTGJY-GNSLJVCWSA-N
|
| InChi Code |
InChI=1S/C24H32O5/c1-5-20(28)29-24(14(2)25)11-9-18-17-7-6-15-12-16(26)8-10-22(15,3)21(17)19(27)13-23(18,24)4/h8,10,12,17-19,21,27H,5-7,9,11,13H2,1-4H3/t17-,18-,19-,21+,22-,23-,24-/m0/s1
|
| Chemical Name |
[(8S,9S,10R,11S,13S,14S,17R)-17-acetyl-11-hydroxy-10,13-dimethyl-3-oxo-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-17-yl] propanoate
|
| Synonyms |
RD-20000;RD 20000;RD20000
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~250 mg/mL (~624.20 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (5.19 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (5.19 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (5.19 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.4968 mL | 12.4841 mL | 24.9682 mL | |
| 5 mM | 0.4994 mL | 2.4968 mL | 4.9936 mL | |
| 10 mM | 0.2497 mL | 1.2484 mL | 2.4968 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
